[{"address1": "325 East Middlefield Road", "city": "Mountain View", "state": "CA", "zip": "94043", "country": "United States", "phone": "650 965 7873", "website": "https://igmbio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.", "fullTimeEmployees": 224, "companyOfficers": [{"maxAge": 1, "name": "Mr. Fred M. Schwarzer J.D.", "age": 70, "title": "CEO, President & Director", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 1002535, "exercisedValue": 0, "unexercisedValue": 1970352}, {"maxAge": 1, "name": "Dr. Bruce A. Keyt Ph.D.", "age": 70, "title": "Chief Scientific Officer", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 713784, "exercisedValue": 0, "unexercisedValue": 1331868}, {"maxAge": 1, "name": "Dr. Chris H. Takimoto FACP, M.D., Ph.D.", "age": 64, "title": "Chief Medical Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 705392, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Misbah  Tahir", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 957600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. TS  Harigopal", "title": "Senior Vice President of Group Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Paul C. Graffagnino", "title": "Senior Vice President of Legal Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Suzette  Tauber", "age": 59, "title": "Chief Human Resources Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Angus M. Sinclair Ph.D.", "title": "Senior Vice President of Immuno-Oncology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lisa L. Decker Ph.D.", "age": 53, "title": "Chief Business Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 528182, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marvin S. Peterson Ph.D.", "title": "Executive Vice President of Process Development & Manufacturing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 9.43, "open": 9.73, "dayLow": 9.72, "dayHigh": 10.19, "regularMarketPreviousClose": 9.43, "regularMarketOpen": 9.73, "regularMarketDayLow": 9.72, "regularMarketDayHigh": 10.19, "beta": 0.251, "forwardPE": -3.4965274, "volume": 181785, "regularMarketVolume": 181785, "averageVolume": 292537, "averageVolume10days": 380660, "averageDailyVolume10Day": 380660, "bid": 10.03, "ask": 10.13, "bidSize": 200, "askSize": 100, "marketCap": 594799616, "fiftyTwoWeekLow": 3.81, "fiftyTwoWeekHigh": 17.7, "priceToSalesTrailing12Months": 279.24866, "fiftyDayAverage": 9.9964, "twoHundredDayAverage": 8.524925, "currency": "USD", "enterpriseValue": 294809952, "floatShares": 11768487, "sharesOutstanding": 33566100, "sharesShort": 5246645, "sharesShortPriorMonth": 4758131, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0888, "heldPercentInsiders": 0.35192, "heldPercentInstitutions": 0.67550004, "shortRatio": 23.48, "shortPercentOfFloat": 0.35689998, "bookValue": 3.463, "priceToBook": 2.9078832, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -246416000, "trailingEps": -4.71, "forwardEps": -2.88, "enterpriseToRevenue": 138.408, "enterpriseToEbitda": -1.164, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "IGMS", "underlyingSymbol": "IGMS", "shortName": "IGM Biosciences, Inc.", "longName": "IGM Biosciences, Inc.", "firstTradeDateEpochUtc": 1568813400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ec470288-8a03-31b9-966a-7fa24c6a00fa", "gmtOffSetMilliseconds": -14400000, "currentPrice": 10.07, "targetHighPrice": 48.0, "targetLowPrice": 12.0, "targetMeanPrice": 21.22, "targetMedianPrice": 20.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 337676992, "totalCashPerShare": 5.744, "ebitda": -253358000, "totalDebt": 40506000, "quickRatio": 7.968, "currentRatio": 8.182, "totalRevenue": 2130000, "debtToEquity": 19.931, "revenuePerShare": 0.041, "returnOnAssets": -0.34907, "returnOnEquity": -1.00476, "freeCashflow": -121961872, "operatingCashflow": -192231008, "revenueGrowth": 0.75, "operatingMargins": -97.224266, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-04"}]